358 related articles for article (PubMed ID: 27631426)
1. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
2. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
5. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
[TBL] [Abstract][Full Text] [Related]
7. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
[TBL] [Abstract][Full Text] [Related]
8. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
9. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
Naito M; Yamamoto T; Hara S; Shimamoto C; Miwa Y
Chemotherapy; 2017; 62(1):23-29. PubMed ID: 27229894
[TBL] [Abstract][Full Text] [Related]
11. Better compliance with the guidelines on hand-foot syndrome in patients treated with capecitabine in colorectal and breast cancer as a result of nursing education.
Krzemieniecki K; Zygulska AL; Kucharz J; Stokłosa
Przegl Lek; 2016; 73(7):460-4. PubMed ID: 29676887
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
[TBL] [Abstract][Full Text] [Related]
13. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
[TBL] [Abstract][Full Text] [Related]
15. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
Zhao J; Zhang X; Cui X; Wang D; Zhang B; Ban L
Oncol Res; 2020 Feb; 28(1):103-106. PubMed ID: 31558182
[TBL] [Abstract][Full Text] [Related]
16. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
17. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
18. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.
Chen M; Chen J; Peng X; Xu Z; Shao J; Zhu Y; Li G; Zhu H; Yang B; Luo P; He Q
Environ Toxicol Pharmacol; 2017 Jan; 49():81-88. PubMed ID: 27951409
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]